MedTrace Logo

Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis

NCT06816953 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-02-10

No results posted yet for this study

Summary

Patients with severe hemophilia A often develop joint complication requiring careful monitoring. This study aimed to compare the effectiveness of standard low dose weight-based FVIII concentrates (CFCs) prophylaxis with pharmacokinetic-guided extended half-life FVIII concentrates (eHLFVIII) using cartilage biomarkers and HEAD-US score.

Conditions

Interventions

DIAGNOSTIC_TEST

HEAD-US

HEAD-US for evaluate haemophilic arthropathy in 6 joints. (Elbow, Knee, Ankle)

DIAGNOSTIC_TEST

Urinary carboxy-terminal cross linked telopeptide of type II collagen

Cartilage biomarker represent cartilage degradation

DIAGNOSTIC_TEST

Inflammatory markers

Inflammatory markers included CBC, Ferritin, ESR, CRP

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2025-01-30
Completion
2025-02-28

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06816953 on ClinicalTrials.gov